Partial agonists in schizophrenia-why some work and others do not: Insights from preclinical animal models

International Journal of Neuropsychopharmacology

Volumn 14, Issue 9, 2011, Pages 1165-1178

  Natesan, Sridhar ^a   Reckless, Greg E ^b   Barlow, Karen B L ^b   Nobrega, José N ^b,c   Kapur, Shitij ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal models; antipsychotic; partial agonist; schizophrenia

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; 7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; ARIPIPRAZOLE; BIFEPRUNOX; DESIPRAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PRECLAMOL; PROLACTIN; PROTEIN FOS; TERGURIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NERVE PROTEIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN C FOS; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; DISORDERS OF HORMONE METABOLISM; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; IC 50; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTANEMIA; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; ANIMAL; COMPARATIVE STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; NUCLEUS ACCUMBENS; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NERVE TISSUE PROTEINS; NEURONS; NUCLEUS ACCUMBENS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-FOS; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84856067612     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001343     Document Type: Article

References (62)

1. Abi-Dargham A (2004). Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology 7 (Suppl. 1), S1-S5. (Pubitemid 38436990)
2. Agid O, Kapur S, Remington G (2008). Emerging drugs for schizophrenia. Expert Opinion on Emerging Drugs 13, 479-495.
3. Banno K, Fujioka T, Kikuchi T, Oshiro Y, et al. (1988). Studies on 2(1H)-quinolinone derivatives as neuroleptic agents I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives. Chemistry and Pharmceutical Bulletin (Tokyo) 36, 4377-4388. (Pubitemid 19005521)
4. Barbato LM, Potkin SG, Heisterberg J, Yeung PP, Shapira NA (2006). A randomized, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacebrations of schizophrenia. Neuropsychopharmacology 31, S251-S252.
5. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, et al. (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273. (Pubitemid 41032989)
6. Bolonna AA, Kerwin RW (2005). Partial agonism and schizophrenia. British Journal of Psychiatry 186, 7-10. (Pubitemid 40070537)
7. Breese GR, Traylor TD (1971). Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. British Journal of Pharmacology 42, 88-99.
8. Brennan JA, Graf R, Grauer SM, Navarra RL, et al. (2010). WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. Journal of Pharmacology and Experimental Therapeutics 332, 190-201.
9. Casey DE, Sands EE, Heisterberg J, Yang HM (2008). Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia : results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berlin) 200, 317-331.
10. Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K (1990). D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37, 287-294. (Pubitemid 20268182)
11. Feenstra RW, de Moes J, Hofma JJ, Kling H, et al. (2001). New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorganic and Medicinal Chemistry Letters 11, 2345-2349. (Pubitemid 32781696)
12. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia : version III-the final common pathway. Schizophrenia Bulletin 35, 549-562.
13. Kane JM, Carson WH, Saha AR, McQuade RD, et al. (2002). Efficacy and safety of aripiprazole and haloperidol vs. placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63, 763-771.
14. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 1081-1090. (Pubitemid 37464954)
15. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, et al. (1995). 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Journal of Pharmacology and Experimental Therapeutics 274, 329-336.
16. Kim JR, Seo HB, Cho JY, Kang DH, et al. (2008). Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. British Journal of Clinical Pharmacology 66, 802-810.
17. Kiss B, Horvath A, Nemethy Z, Schmidt E, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. Journal of Pharmacology and Experimental Therapeutics 333, 328-340.
18. Kiuchi K, Hirata Y, Minami M, Nagatsu T (1988). Effect of 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)-2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices. Life Sciences 42, 343-349. (Pubitemid 18038337)
19. Klewe IV, Nielsen SM, Tarpo L, Urizar E, et al. (2008). Recruitment of beta-arrestin2 to the dopamine D2 receptor : insights into anti-psychotic and anti-parkinsonian drug receptor signalling. Neuropharmacology 54, 1215-1222.
20. Koller WC, Herbster G (1987). Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease. Neurology 37, 723-727. (Pubitemid 17057960)
21. Krause W, Trager H, Kuhne G, Sauerbrey N, et al. (1990). Pharmacokinetics and endocrine effects of terguride in healthy subjects. European Journal of Clinical Pharmacology 38, 609-615. (Pubitemid 20206037)
22. Lahti AC, Weiler MA, Corey PK, Lahti RA, et al. (1998). Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n- propylpiperidine (preclamol) in schizophrenia. Biological Psychiatry 43, 2-11. (Pubitemid 28059067)
23. Largent BL, Gundlach AL, Snyder SH (1984). Psychotomimetic opiate receptors labelled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl) piperidine. Proceedings of the National Academy of Sciences USA 81, 4983-4987. (Pubitemid 14066238)
24. Lawler CP, Prioleau C, Lewis MM, Mak C, et al. (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20, 612-627. (Pubitemid 29189265)
25. Lieberman JA (2004). Dopamine partial agonists : a new class of antipsychotic. CNS Drugs 18, 251-267. (Pubitemid 38393435)
26. Mamo D, Graff A, Mizrahi R, Shammi CM, et al. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia : a triple tracer PET study. American Journal of Psychiatry 164, 1411-1417. (Pubitemid 47461142)
27. Marshall JF, Ungerstedt U (1977). Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Europena Journal of Pharmacology 41, 361-367. (Pubitemid 8034143)
28. Masri B, Salahpour A, Didriksen M, Ghisi V, et al. (2008). Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proceedings of the National Academy of Sciences USA 105, 13656-13661.
29. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, et al. (2000). S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors : II. Functional and behavioral profile compared with GR218,231 and L741,626. Journal of Pharmacology and Experimental Therapeutics 293, 1063-1073. (Pubitemid 30417877)
30. Millan MJ, Maiofiss L, Cussac D, Audinot V, et al. (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303, 791-804. (Pubitemid 35231256)
31. Miller JC (1990). Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. Journal of Neurochemistry 54, 1453-1455.
32. Murasaki M, Miura S, Ishigooka J, Ishii Y, et al. (1988). Phase 1 study of a new antipsychotic drug, OPC-4392. Progress in Neuropsychopharmacology and Biological Psychiatry 12, 793-802.
33. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2008). Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophrenia Research 105, 224-235.
34. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors : comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
35. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, et al. (2005). Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors : affinity, efficacy and potential implications for treatment of schizophrenia. International Journal of Neuropsychopharmacology 8, 341-356. (Pubitemid 41002489)
36. Newman-Tancredi A, Cussac D, Depoortere R (2007). Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Current Opinion Investigational Drugs 8, 539-554. (Pubitemid 47016322)
37. Olbrich R, Schanz H (1991). An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. Journal of Neural Transmission General Section 84, 233-236.
38. Patil ST, Zhang L, Martenyi F, Lowe SL, et al. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia : a randomized Phase 2 clinical trial. Nature Medicine 13, 1102-1107. (Pubitemid 47517511)
39. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press.
40. Potkin SG, Saha AR, Kujawa MJ, Carson WH, et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Archieves of General Psychiatry 60, 681-690. (Pubitemid 36818630)
41. Rajagopal S, Rajagopal K, Lefkowitz RJ (2010). Teaching old receptors new tricks : biasing seven-transmembrane receptors. Nature Reviews Drug Discovery 9, 373-386.
42. Reavill C, Taylor SG, Wood MD, Ashmeade T, et al. (2000). Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. Journal of Pharmacology and Experimental Therapeutics 294, 1154-1165. (Pubitemid 30666872)
43. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Journal of Pharmacology and Experimental Therapeutics 271, 1058-1066. (Pubitemid 24377799)
44. Rotella DP, McFarlane GR, Greenfield A, Grosanu C, et al. (2009). Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic and Medicinal Chemistry Letters 19, 5552-5555.
45. Shapiro DA, Renock S, Arrington E, Chiodo LA, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411. (Pubitemid 41070874)
46. Sheng M, Greenberg ME (1990). The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4, 477-485. (Pubitemid 20160837)
47. Stahl SM (2001). Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, 'Goldilocks' actions at dopamine receptors. Journal of Clinical Psychiatry 62, 841-842. (Pubitemid 33131168)
48. Strange PG (2007). Mechanisms underlying agonist efficacy. Biochemical Society Transactions 35, 733-736. (Pubitemid 47310356)
49. Strange PG (2008). Antipsychotic drug action : antagonism, inverse agonism or partial agonism. Trends in Pharmacological Sciences 29, 314-321.
50. Sumner BE, Cruise LA, Slattery DA, Hill DR, et al. (2004). Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berlin) 171, 306-321. (Pubitemid 38200069)
51. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2008). Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European Journal of Pharmacology 597, 27-33.
52. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2009). Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. European Journal of Pharmacology 607, 35-40.
53. Tadori Y, Miwa T, Tottori K, Burris KD, et al. (2005). Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology 515, 10-19. (Pubitemid 40779262)
54. Tamminga CA (2002). Partial dopamine agonists in the treatment of psychosis. Journal of Neural Transmission 109, 411-420. (Pubitemid 34251643)
55. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A (1992). Pharmacologic properties of (-)-3PPP (preclamol) in man. Journal of Neural Transmission. General Section 88, 165-175.
56. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007). Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32, 67-77. (Pubitemid 44967785)
57. van Os J, Kapur S (2009). Schizophrenia. Lancet 374, 635-645.
58. Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berlin) 150, 422-429. (Pubitemid 30470221)
59. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001). Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25, 633-641. (Pubitemid 32995945)
60. Wikstrom H, Sanchez D, Lindberg P, Hacksell U, et al. (1984). Resolved 3-(3-hydroxyphenyl)-N-npropylpiperidine and its analogues: central dopamine receptor activity. Journal of Medicinal Chemistry 27, 1030-1036. (Pubitemid 14057365)
61. Wood MD, Scott C, Clarke K, Westaway J, et al. (2006). Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European Journal of Pharmacology 546, 88-94. (Pubitemid 44339632)
62. Yan Y, Zhou P, Rotella DP, Feenstra R, et al. (2010). Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia. Bioorganic and Medicinal Chemistry Letters 20, 2983-2986.